BIOMAT Database Logo BIOMAT Database Logo

Development of an orally active tripeptide arginal thrombin inhibitor. 1998

R T Shuman, and P D Gesellchen
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.

UI MeSH Term Description Entries
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000991 Antithrombins Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. Antithrombin,Direct Antithrombin,Direct Antithrombins,Direct Thrombin Inhibitor,Direct Thrombin Inhibitors,Antithrombin, Direct,Antithrombins, Direct,Inhibitor, Direct Thrombin,Thrombin Inhibitor, Direct,Thrombin Inhibitors, Direct
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

R T Shuman, and P D Gesellchen
Ximelagatran: an orally active direct thrombin inhibitor.
July 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
R T Shuman, and P D Gesellchen
Retro-binding thrombin active site inhibitors: identification of an orally active inhibitor of thrombin catalytic activity.
November 2002, Bioorganic & medicinal chemistry letters,
R T Shuman, and P D Gesellchen
SSR182289A, a selective and potent orally active thrombin inhibitor.
April 2004, Bioorganic & medicinal chemistry,
R T Shuman, and P D Gesellchen
Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
February 2003, The Journal of pharmacology and experimental therapeutics,
R T Shuman, and P D Gesellchen
Strategies and progress towards the ideal orally active thrombin inhibitor.
December 1999, Current pharmaceutical design,
R T Shuman, and P D Gesellchen
An orally active inhibitor of renin.
December 1986, Hypertension (Dallas, Tex. : 1979),
R T Shuman, and P D Gesellchen
Orally active direct thrombin inhibitors.
May 2003, Seminars in vascular medicine,
R T Shuman, and P D Gesellchen
Aliskiren: An orally active renin inhibitor.
April 2011, Journal of pharmacy & bioallied sciences,
R T Shuman, and P D Gesellchen
Pharmacokinetics and toxicokinetics of an orally active tripeptide, IRI-695, in animals.
January 1996, Biopharmaceutics & drug disposition,
R T Shuman, and P D Gesellchen
Challenges in the development of orally bioavailable thrombin active site inhibitors.
September 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Copied contents to your clipboard!